2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6301 Real-world treatment patterns in 2nd and 3rd line relapsed/refractory multiple myeloma in the United States: A retrospective electronic health record study (2023–2025)

Jodi Lipof, MD, James Farrell2, Ann-Sophie Demers3, Méloë Maigné4, Sara Johnson, MSc5, David Hughes, PharmD, BCOP, MPH6, Rickard Sandin, PhD7, Tommy Price8, Joshua Richter I, MD9
1 Division of Hematology/Oncology, University of California San Francisco, San Francisco, California, United States
2 Pfizer Ltd, County Kildare, Ireland
3 STATLOG Inc, Quebec, Canada
4 STATLOG Inc, Quebec, Canada
5 STATLOG Inc, Quebec, Canada
6 Pfizer Ltd, Cambridge, Massachusetts, United States
7 Pfizer Ltd, Stockholm, Sweden
8 Pfizer Ltd, Cardiff, United Kingdom
9 Tisch Cancer Institute: Icahn School of Medicine at Mount Sinai, New York, United States

Background

The relapsed/refractory multiple myeloma (RRMM) treatment landscape has evolved rapidly, with anti-CD38 monoclonal antibodies, immunomodulatory drugs (IMiDs), and proteasome inhibitors (PIs) central to current standard of care. Novel immune effector therapies (chimeric antigen receptor T-cell (CAR-T) therapies and bispecific antibodies) are entering routine practice. Contemporary real-world (RW) evidence describing treatment patterns in 2nd-line (2L) and 3rd-line (3L) RRMM is limited, yet essential for clinical trial contextualisation and health technology assessment (HTA) submissions.

Aims

To describe treatment patterns (combinations, drug classes, and individual agents) and patient characteristics in US patients with RRMM initiating 2L or 3L therapy between 2023 and 2025, and to evaluate temporal trends across three annual sub-periods.

Methods

This retrospective study used de-identified US electronic health record (EHR) data from the COTA database (>500,000 multiple myeloma [MM] patients; >200 sites of care; data to November 2025). Patients with MM initiating 2L or 3L therapy (index date) between 2023 and 2025 were included without treatment history restrictions (N=1459 lines of therapy [LOTs]). The same patient could contribute both a 2L and 3L LOT; N (%) were calculated using total LOTs. Results were stratified by LOT and by year (2023, 2024, 2025). All analyses were descriptive.

Results

Patients had a mean age of 68.2 years (standard deviation [SD] 11.1); 55.8% were male. Race was 57.8% White, 16.4% Black or African American, and ethnicity was 21.0% Hispanic or Latino. Of LOTs, 54.2% were 2L and 45.8% were 3L. Mean Charlson Comorbidity Index (CCI) score was 2.6 (SD 1.0). High-risk cytogenetics were present in 20.0% of patients. Prior PI exposure was 92.3%, prior IMiD 83.6%, and prior anti-CD38 34.2%. Triple-class exposure (PI + IMiD + anti-CD38) rose from 20.8% (2023) to 37.3% (2025). Lenalidomide and anti-CD38 refractoriness was 31.4% and 16.5% respectively.

Across 2L and 3L combined, IMiD (61.5%), anti-CD38 (60.7%), and PI (48.6%) were the most used drug classes. The leading regimens were daratumumab (DARA) + pomalidomide (POM) (13.5%), DARA + lenalidomide (LEN) 12.7%), and carfilzomib (CARF) + DARA (8.1%). At the class combination level, anti-CD38+IMiD was the most common (27.3%), followed by anti-CD38+PI (15.8%) and IMiD+PI (10.5%). All combinations are considered with/ without the addition of dexamethasone.

At 2L only, DARA+POM (11.8%) and DARA+LEN (15.4%) were the most used combinations. At 3L, DARA+POM (15.6%) use exceeded DARA+LEN (9.6%) use alongside more diverse regimens reflecting prior exposure.

From 2023 to 2025, anti-CD38+IMiD combinations increased from 24.6% to 37.8% and DARA+LEN use in 2L rose from 10.9% (2023) to 21.2% (2025). CAR-T use in the index LOT increased from 0.3% (2023) to 7.8% (2025), and bispecific antibodies from 0.4% to 3.7% (however, bispecific antibodies were not approved at 2L or 3L during the timeframe of the analysis).

Summary

In this large contemporaneous US RW study, daratumumab-based doublets dominated 2L/3L RRMM treatment across 2023–2025. Triple-class prior exposure increased substantially over time, with nearly 40% of patients triple-class exposed by 2025.

These data provide a critical contemporary reference for trial contextualization, external control arm development, and HTA evidence planning in RRMM.

Jodi Lipof, MD: Eli Lilly/ Kelonia Therapeutics - Research Funding; CellCentric - Research Funding; Janssen - Research Funding; Janssen - Patents & Royalties; CellCentric - Patents & Royalties; Eli Lilly/ Kelonia Therapeutics - Patents & Royalties; Sanofi - Consultancy (Includes expert testimony); Arcellx - Consultancy (Includes expert testimony); Astrazeneca - Consultancy (Includes expert testimony); Kite Pharma - Consultancy (Includes expert testimony)